VIR — Vir Biotechnology, Inc.

Summary of Vir Biotechnology's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• R&D Expenses: Decreased to $456 million in 2025 from $507 million in 2024 (10% reduction).
• SG&A Expenses: Reduced to $92 million in 2025 from $119 million in the prior year (23% decrease).
• Net Loss: Reported at $438 million, down from $522 million in 2024.
• Cash Position: Ended 2025 with approximately $782 million in cash and investments, not including the upcoming Astellas collaboration funds. Cash runway extended into Q2 2028.
• Collaboration with Astellas: Vir will receive $335 million upfront, including $240 million in cash and $75 million as equity investment. The total potential financial impact of the collaboration is $1.7 billion, including milestone payments.

2. Strategic Updates and Business Highlights

• Announced a strategic collaboration with Astellas for VIR-5500, a PSMA-targeted T-cell engager for prostate cancer, aiming to accelerate development and commercialization.
• Phase I data for VIR-5500 demonstrated a favorable safety and efficacy profile, with significant PSA declines and no observed dose-limiting toxicities.
• The collaboration is expected to enhance the development of VIR-5500 across various lines of prostate cancer treatment, leveraging Astellas' expertise and resources.
• Vir plans to initiate expansion cohorts for VIR-5500 in Q2 2026, focusing on late-line mCRPC, first-line mCRPC in combination with enzalutamide, and metastatic hormone-sensitive prostate cancer.

3. Forward Guidance and Outlook

• Anticipate moving into Phase III trials for VIR-5500 by 2027, with a focus on optimizing dosing and expanding indications.
• The collaboration with Astellas is expected to provide a capital-efficient structure that reduces development risk while expanding patient access.
• Plans to share Phase I data for their HER2 program in the second half of 2026, with ongoing development of additional preclinical programs.

4. Bad News, Challenges, or Points of Concern

• The company operates in a highly competitive oncology landscape, with significant unmet needs in prostate cancer treatment.
• While the Phase I data is promising, the long-term durability of responses and overall survival benefits remain to be fully established.
• The need for ongoing optimization and potential adjustments in dosing strategies could present operational challenges.

5. Notable Q&A Insights

• Analysts inquired about the correlation between PSA declines and potential progression-free survival (PFS), with the company indicating that deeper PSA declines are generally associated with more durable responses.
• Questions regarding the potential for combining VIR-5500 with other therapies beyond enzalutamide were raised, with Vir indicating that future combination strategies will be determined in collaboration with Astellas.
• The company confirmed that the go-forward dose for VIR-5500 will be in the range of 3,000 to 3,500 micrograms per kilogram, but specific details will be communicated later due to the partnership dynamics.
• Concerns about the lack of high-grade cytokine release syndrome (CRS) at higher doses were addressed, emphasizing the favorable safety profile and the absence of dose-limiting toxicities.

Overall, Vir Biotechnology's strategic collaboration with Astellas and the promising Phase I data for VIR-5500 position the company for significant advancements in the oncology space, despite the inherent challenges and competitive pressures in the market.